Algorithm feasibility of a novel oxygen delivery system using comfort mode and closed-loop oxygen control in participants with chronic lung disease

Fisher and Paykel0 个研究点目标入组 8 人开始时间: 2019年1月8日最近更新: 2021年3月1日

适应症

试验速览

暂无简介。

•1. Doctor’s diagnosis of a chronic respiratory disease such as COPD, bronchiectasis and Interstitial Lung Disease
•2. Stable respiratory state with no exacerbation in last 4 weeks
•1. Doctor’s diagnosis of a chronic respiratory disease such as COPD, bronchiectasis and Interstitial Lung Disease
•2. Prescribed long term oxygen therapy (LTOT) for use at rest
•3. Stable respiratory state with no exacerbation in last 4 weeks
•4. Hypercapnic (PtCO2 >45mmHg), with SpO2 <88% at rest breathing room air OR Normocapnic (PtCO2 less than or equal to 45mmHg), with SpO2<92% at rest breathing room air

•Group A and B
•1. Age <18
•2. Cognitive impairment
•3. Diagnosis of a notifiable disease (eg. hepatitis, TB, rheumatic fever, HIV, gastroenteritis)
•4. The presence of an implantable Medical Device (eg. pacemaker, defibrillator, neurostimulator or insulin pump)
•5. Known infection or colonization with multidrug resistant bacteria, Pseudomonas species, Burkholderia Cepacia or mycobacteria
•6. The presence of an implantable Medical Device (eg. Pacemaker, defibrillator, neurostimulator, or insulin pump).
•7. Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.
•Group B ONLY
•1. Inability to tolerate an interruption in oxygen therapy
•2. Requirement for more than 4L/min LTOT at rest

发起方

Fisher and Paykel